Alexion Pharmaceuticals Inc.

NASDAQ:ALXN  
181.66
-0.33 (-0.18%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)40.08B
Current PE74.91
Forward PE 13.52
2yr Forward PE 12.62
See more stats
Estimates Current Quarter
Revenue$1.65 Billion
Adjusted EPS$3.33
See more estimates
10-Day MA$178.43
50-Day MA$169.08
200-Day MA$144.49
See more pivots

Alexion Pharmaceuticals Inc. Stock, NASDAQ:ALXN

121 Seaport Boulevard, Boston, Massachusetts 02210
United States of America
Phone: +1.475.230.2596
Number of Employees: 3837

Description

Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.